On November 6, BEONE MEDICINES fell 3.46% intraday in Regular Trading, trading at HK$245.0, with turnover of HK$498 million.

The clearest recent catalyst is that the company had just reported strong third-quarter results and raised full-year guidance for the third time, but the latest market commentary said the share-price weakness reflected profit-taking after the earnings-driven rally.

The company reported first-nine-month revenue of RMB34.993 billion, up 26.8% year over year, and net profit attributable to shareholders of RMB6.055 billion, up 431.8%. Third-quarter global revenue reached US$1.9 billion, while adjusted EPS of US$4.59 and sales of US$1.890 billion both exceeded market expectations. Management also raised full-year revenue guidance to RMB46.3 billion-RMB47.0 billion, versus the prior RMB44.9 billion-RMB46.2 billion range, and lifted operating-income-related guidance as well.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)